Ian Clements
2021
In 2021, Ian Clements earned a total compensation of $2M as Chief Financial Officer at Mirum Pharmaceuticals, a 43% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $212,500 |
|---|---|
| Option Awards | $1,091,550 |
| Salary | $425,000 |
| Stock Awards | $239,906 |
| Other | $11,600 |
| Total | $1,980,556 |
Clements received $1.1M in option awards, accounting for 55% of the total pay in 2021.
Clements also received $212.5K in non-equity incentive plan, $425K in salary, $239.9K in stock awards and $11.6K in other compensation.
Rankings
In 2021, Ian Clements' compensation ranked 6,084th out of 12,406 executives tracked by ExecPay. In other words, Clements earned more than 51.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,084 out of 12,406 | 51st |
Division Manufacturing | 2,569 out of 5,492 | 53rd |
Major group Chemicals And Allied Products | 1,124 out of 2,368 | 53rd |
Industry group Drugs | 1,001 out of 2,089 | 52nd |
Industry Pharmaceutical Preparations | 723 out of 1,536 | 53rd |
Source: SEC filing on April 22, 2022.
Clements' colleagues
We found three more compensation records of executives who worked with Ian Clements at Mirum Pharmaceuticals in 2021.